ESSA Pharma Inc.

NasdaqCM EPIX

ESSA Pharma Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 126.76 M

ESSA Pharma Inc. Cash and Short-Term Investments is USD 126.76 M for the quarter ending September 30, 2024. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

ESSA Pharma Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 57.08 M, a -70.72% change year over year.
ESSA Pharma Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 194.93 M, a 246.10% change year over year.
ESSA Pharma Inc. Cash and Short-Term Investments for the quarter ending September 30, 2020 was USD 56.32 M, a 5.62% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: EPIX

ESSA Pharma Inc.

CEO	Dr. David Ross Parkinson M.D.
IPO Date	March 13, 2015
Location	Canada
Headquarters	999 West Broadway
Employees	50
Sector	Healthcare
Industries Biotechnology Clinical Trials Personal Care Pharmaceuticals

Description

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Key trends

Past 5 years